Results show a 24-month survival rate of 29.4% for mitazalimab in combination with mFOLFIRINOX, triple that of chemotherapy aloneTopline data from the 450 µg/kg cohort, further strengthens the rationa ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results